Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

Salvatore Siena,Andrea Sartore-Bianchi,Nicola Personeni,Filippo Pietrantonio,Giovanni Germano,Alessio Amatu,Emanuela Bonoldi,Emanuele Valtorta,Ludovic Barault,Federica Di Nicolantonio,Giulia Siravegna,Giovanni Crisafulli,Lorenza Rimassa,Filippo de Braud,Armando Santoro,Luca Lazzari,Paolo Luraghi,Nabil Amirouchene-Angelozzi,Alberto Bardelli,Silvia Marsoni

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

2019

TPS2659Background: Metastatic colorectal cancer (CRC) harbouring genetic defects in the mismatch-repair pathway (MMRd) presents with a high tumor mutational burden (TMB), and is highly sensitive to...

Keywords:

Somatic hypermutation
Oncology
Colorectal cancer
Pathology
Pembrolizumab
Internal medicine
Medicine
highly sensitive
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations